GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

and the company states that 40% of the world’s children receive a GSK vaccine each year. A key product for the company is Shingrix (recombinant zoster vaccine), which is a vaccine that protects ...

Last July, GSK also bagged FDA approval for use ... Another company developing a vaccine for herpes zoster is US biotech Curevo Vaccine, whose adjuvanted subunit vaccine CRV-101 is in early ...

During this conference where the launch of the "Shingrix" vaccine was announced, Engineer Hassan Fahmi General Manager of GSK Egypt ... response to the varicella-zoster virus gradually becomes ...

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...